Supporting drug development for neglected tropical diseases using mathematical modelling

24 Apr 2021
Martin Walker, PhD, Jonathan I D Hamley, PhD, Philip Milton, MSc, Frédéric Monnot, Pharm D, Sally Kinrade, B. Pharm MPH, Sabine Specht, PhD, Bélen Pedrique, MSc, Maria-Gloria Basáñez, PhD

Drug-based interventions are at the heart of global efforts to reach elimination as a public health problem (trachoma, soil-transmitted helminthiases, schistosomiasis, lymphatic filariasis) or elimination of transmission (onchocerciasis) for five of the most prevalent neglected tropical diseases tackled via the World Health Organization preventive chemotherapy strategy. While for some of these diseases there is optimism that currently available drugs will be sufficient to achieve the proposed elimination goals, for others—particularly onchocerciasis—there is a growing consensus that novel therapeutic options will be needed. Since in this area no high return of investment is possible, minimizing wasted money and resources is essential. Here, we use illustrative results to show how mathematical modelling can guide the drug development pathway, yielding resource-saving and efficiency payoffs, from the refinement of target product profiles and intended context of use, to the design of clinical trials.